Immune checkpoint inhibitors for patients with cancer may be associated with an increased risk for psoriasis when compared ...

Experts discuss Robert’s journey with HER2-positive upper gastrointestinal (GI) cancer, highlighting key treatment approaches and challenges.

Experts discuss the most common adverse events associated with the FOLFOX regimen and effective strategies for early ...

Experts discuss Robert’s journey with HER2-positive upper gastrointestinal (GI) cancer, highlighting key treatment approaches ...

The role of oncology nurses and APPs in research is largely to stay abreast of trials that may be useful to patients and recommend them whenever possible, according to Erica Doubleday, MS, FNP-C, BSN, ...

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, ...

New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal ...

Men with intermediate-risk prostate cancer and high PSA levels before HIFU treatment had a greater risk of both overall recurrence and treatment failure. Men with intermediate-risk prostate cancer and ...

Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone. Nivolumab (Opdivo) plus cabozantinib ...

The phase 3 ARANOTE trial (NCT04736199) found that adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) improved efficacy outcomes in patients with metastatic hormone-sensitive prostate ...

Improved progression-free survival in metastatic urothelial carcinoma was observed in patients experiencing neuropathy, skin rash, and hyperglycemia following enfortumab vedotin.